Heinzer H, König F, Klutmann S
Prostatakrebszentrum, Martini-Klinik am Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland,
Urologe A. 2014 Apr;53(4):519-23. doi: 10.1007/s00120-014-3436-1.
Radium-223 dichloride (Ra-223) is an alpha emitter with low toxicity for the treatment of patients with castrations-resistant prostate cancer (CRPC) and symptomatic bone metastases showing a 30% reduction in the risk of death, as compared to placebo. Because of the favorable physical and chemical characteristics, Ra-223 can be handled easily in daily practice based on interdisciplinary co-operation between urology and nuclear medicine. Ra-223 has been approved under the product name Xofigo® by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
二氯化镭-223（Ra-223）是一种α发射体，对去势抵抗性前列腺癌（CRPC）和有症状骨转移的患者治疗毒性较低，与安慰剂相比，死亡风险降低了30%。由于其良好的物理和化学特性，基于泌尿外科和核医学之间的跨学科合作，Ra-223在日常实践中易于操作。Ra-223已以Xofigo®的商品名获得美国食品药品监督管理局（FDA）和欧洲药品管理局（EMA）的批准。
Zotero 插件